Saharsh Davuluri, Neuland Labs, urges API and peptide automation by 2026 to match modern biologics standards.
Eli Lilly and Company has announced plans to invest $6.5bn in an active pharmaceutical ingredients (API) manufacturing facility at Generation Park in Houston, in the US state of Texas. The new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback